Patent intelligence · US
US 12109198
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
Patent details — US 12109198
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 8, 2024
- Expiration
- Oct 3, 2044
- Applicant
- Fulcrum Therapeutics, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K31/4355, A61K31/437, A61K45/06
Quick answer
US 12109198 (Macrocyclic azolopyridine derivatives as EED and PRC2 modulators) is held by Fulcrum Therapeutics, Inc.. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/4355, A61K31/437, A61K45/06, A61P, A61P35/00
More from Fulcrum Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11819554
Compositions and methods for modulating FMR1 expression
granted -
US 11590111
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11479770
Use of p38 inhibitors to reduce expression of DUX4
granted -
US 11291659
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10973805
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 10537560
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10342786
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted
Frequently asked questions
What is US patent 12109198?
US 12109198 (Macrocyclic azolopyridine derivatives as EED and PRC2 modulators) is held by Fulcrum Therapeutics, Inc.. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12109198?
Fulcrum Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 12109198 expire?
Our index shows an expiration date of Oct 3, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.